Quantcast
Last updated on April 17, 2014 at 11:16 EDT

Latest Esperance Pharmaceuticals Inc. Stories

2012-08-28 02:28:12

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi?center trial of EP?100 in combination with paclitaxel for patients with advanced ovarian cancer. EP?100 is a targeted membrane?disrupting peptide (tMDP) designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a wide range...

2012-06-04 02:27:12

BATON ROUGE, La., June 4, 2012 /PRNewswire/ -- Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane?disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. EP?100 is designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a wide range of cancers. The Phase 1...

2012-05-17 10:25:26

BATON ROUGE, La., May 17, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced that it has begun enrollment of a Phase 2, randomized, multi-center trial of EP-100 in combination with paclitaxel for the potential treatment of advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over-expressed in a wide...

2012-04-03 06:25:50

BATON ROUGE, La., April 3, 2012 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals presented results from in vitro studies demonstrating synergy of EP-100 in combination with paclitaxel for the potential treatment of luteinizing hormone releasing hormone (LHRH)-receptor positive and multi-drug resistant cancers, including ovarian cancer, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. Results have supported the initiation of a...

2011-06-01 06:00:00

BATON ROUGE, La., June 1, 2011 /PRNewswire/ -- Esperance Pharmaceuticals, Inc. today announced the first closing of a $7.5 million Series B financing. Proceeds from the Series B will support further clinical development of EP-100, the lead cancer-targeting drug candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology and the continued expansion of the Company's pipeline. Sanofi led the Series B funding with an investment of $4.5 million, which includes $1.5 million...

2010-04-20 13:05:00

BATON ROUGE, La., April 20 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells. Results from in vitro and in vivo...

2009-09-10 07:30:00

BATON ROUGE, La., Sept. 10 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone...

2009-04-21 14:01:00

- Company plans initiation of clinical studies; Data to be presented at AACR - BATON ROUGE, La., April 21 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from the Company's preclinical program that support the initiation of clinical trials in cancer. EP-100 is the first candidate from the Company's Cationic Lytic Peptide (CLYP(TM)) platform technology. EP-100 is a targeted membrane-disrupting peptide and is designed to...